Claims
- 1. A process for the preparation of a compound of Formula I ##STR48## and a dihydroxy acid and pharmaceutically acceptable salts thereof, corresponding to the opened lactone ring of a compound of Formula I
- wherein
- R.sub.1 is
- 1-naphthyl,
- 2-naphthyl,
- cyclohexyl,
- cyclohexylmethyl,
- norbornenyl,
- phenyl,
- phenyl substituted with
- fluorine,
- chlorine,
- bromine,
- hydroxyl,
- trifluoromethyl,
- alkyl of from one to four carbon atoms,
- alkoxy of from one to four carbon atoms, or
- alkanoyloxy of from two to eight carbon atoms,
- benzyl,
- 2-, 3-, or 4-pyridinyl, or
- 2-, 3-, or 4-pyridinyl-N-oxide;
- R.sub.2 or R.sub.3 is independently
- hydrogen,
- alkyl of from one to six carbon atoms,
- cyclopropyl,
- cyclobutyl,
- cyclopentyl,
- cyclohexyl,
- phenyl,
- phenyl substituted with
- fluorine,
- chlorine,
- bromine,
- hydroxyl,
- trifluoromethyl,
- alkyl of from one to four carbon atoms, or
- alkoxy of from one to four carbon atoms,
- cyano,
- trifluoromethyl, or --CONR.sub.5 R.sub.6 where R.sub.5 and R.sub.6 are independently
- hydrogen,
- alkyl of from one to six carbon atoms, phenyl,
- phenyl substituted with
- fluorine,
- chlorine,
- bromine,
- cyano, or
- trifluoromethyl;
- R.sub.4 is
- alkyl of from one to six carbon atoms,
- cyclopropyl,
- cyclobutyl,
- cyclopentyl,
- cyclohexyl, or
- trifluoromethyl;
- which comprises:
- (a) reacting 1,6-heptadien-4-ol with an
- (1) alkyl lithium
- (2) followed by iodine and carbon dioxide and
- (3) treating the resulting iodocarbonate intermediate in situ with an alkali or alkaline-earth metal hydroxide or carbonate in an aqueous alcohol at about 0.degree. C. to about 40.degree. C. to afford a compound of Formula IX; ##STR49## (b) treating the compound of Formula IX with (1) an alkali cyanide at about 0.degree. C. to about 40.degree. C. and
- (2) reacting the resulting diol intermediate in situ with a ketal-forming reagent in the presence of camphorsulfonic acid or paratoluenesulfonic acid to afford a compound of Formula VIII ##STR50## wherein R.sub.7 and R.sub.8 are independently hydrogen, alkyl of from one to three carbon atoms, phenyl or R.sub.7 and R.sub.8 taken together as--(CH.sub.2).sub.n --, wherein n is 4 or 5;
- (c) treating the compound of Formula VIII with
- (1) ozone in dichloromethane and
- (2) reacting the resulting intermediate in situ with oxygen triphenylphosphine at about -20.degree. C. to about -78.degree. C. to afford a compound of Formula VII ##STR51## wherein R.sub.7 and R.sub.8 are as defined above; (d) treating the compound of Formula VII with chromium trioxide-sulfuric acid-water at about 0.degree. C. to afford a compound of Formula VI ##STR52## wherein R.sub.7 and R.sub.8 are as defined above; (e) treating the compound of Formula VI with a compound of Formula
- Hal--R.sub.9.sbsb.a
- wherein Hal is halogen and R.sub.9.sbsb.a is alkyl of from one to eight carbon atoms or a three- to six-membered cycloalkyl group, in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene to afford a compound of Formula V.sub.a ##STR53## wherein R.sub.7, R.sub.8, and R.sub.9.sbsb.a are as defined above; or treating the compound of Formula VI with a compound of Formula
- HO--R.sub.9.sbsb.b
- wherein R.sub.9.sbsb.b is tertiary butyl, tertiary amyl, or .alpha., .alpha.-dimethylbenzyl in the presence of an activating agent, a catalytic amount of 4-dimethylaminopyridine and an inert solvent to afford a compound of Formula V.sub.b ##STR54## wherein R.sub.7, R.sub.8, and R.sub.9.sbsb.b are as defined above; (f) treating the compound of Formula V.sub.a with hydrogen in the presence of a noble metal or Raney nickel and acetic or propanoic acid at about 0.degree. C. to about 70.degree. C. to afford a compound of Formula IV.sub.a ##STR55## wherein R.sub.7, R.sub.8, and R.sub.9.sbsb.a are as defined above, or treating the compound of Formula V.sub.b with hydrogen in the presence of a noble metal and acetic or propanoic acid or Raney nickel or Raney cobalt in an inert solvent saturated with anhydrous ammonia or saturated with aqueous ammonium hydroxide or aqueous sodium hydroxide at about 0.degree. C. to about 70 .degree. C. to afford a compound of Formula IV.sub.b ##STR56## wherein R.sub.7, R.sub.8, and R.sub.9.sbsb.b are as defined above; (g) treating the compound of Formulas IV.sub.a with a compound of Formulas III ##STR57## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as defined above in an inert solvent to afford a compound of Formula II.sub.a ##STR58## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, R.sub.8, and R.sub.9.sbsb.a are as defined above, or treating the compound of Formula IV.sub.b with a compound of Formula III in an inert solvent to afford a compound of Formula II.sub.b ##STR59## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.7, R.sub.8, and R.sub.9.sbsb.b are as defined above;
- (h) and finally treating a compound of Formula II.sub.a with
- (1) aqueous hydrochloric acid in the presence of an inert solvent
- (2) followed by hydrolysis with sodium hydroxide
- (3) followed by neutralization with aqueous hydrochloric acid and
- (4) dissolution and/or heating in an inert solvent with concomitant removal of water to give a compound of Formula I, or treating a compound of Formula II.sub.b with
- (1) aqueous hydrochloric acid in the presence of an inert solvent
- (2) followed by addition of sodium hydroxide
- (3) followed by neutralization with aqueous hydrochloric acid and
- (4) dissolution and/or heating in an inert solvent with concomitant removal of water to give a compound of Formula I;
- (i) and if desired converting the resulting compound of Formula I to a dihydroxy acid corresponding to the opened lactone ring of structural Formula I by conventional hydrolysis and further, if desired converting the dihydroxy acid to a corresponding pharmaceutically acceptable salt by conventional means, and if so desired converting the corresponding pharmaceutically acceptable salt to a dihydroxy acid by conventional means, and if so desired converting the dihydroxy acid to a compound of Formula I by heating in an inert solvent.
- 2. A process according to claim 1 wherein the alkyl lithium in step (a) is n-butyllithium.
- 3. A process according to claim 1 wherein the alkali cyanide in step (b) is potassium cyanide.
- 4. A process according to claim 1 wherein the oxidizing reagent in step (d) is chromium trioxide-sulfuric acid-water.
- 5. A process according to claim 1 wherein the catalyst in step (f) for preparing a compound of Formula IV.sub.a is platinum dioxide.
- 6. A process according to claim 1 wherein the catalyst and base in Step (f) for preparing a compound of Formula IV.sub.b are Raney nickel and anhydrous ammonia, respectively.
- 7. A process according to claim 1 wherein the acid in step (h) is hydrochloric acid.
- 8. A process according to claim 1 wherein the base in step (h) is sodium hydroxide.
- 9. A process according to claim 1 wherein R.sub.1 is 1-naphthyl, norbornenyl, phenyl, or phenyl substituted with fluorine, chlorine, bromine, hydroxyl, trifluoromethyl, alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms.
- 10. A process according to claim 9 wherein R.sub.4 is alkyl of from one to six carbon atoms, cyclopropyl, or trifluoromethyl.
- 11. A process according to claim 1 and for the preparation of a compound selected from the group consisting of:
- trans-6-[2-[2-(4 -fluorophenyl)-5-(trifluoro-methyl)-1H-pyrrol-1-yl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;
- trans-6-[2-[2-(4-fluorophenyl)-5-methyl-1H-pyrrol-1-yl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;
- trans-6-[2-[2-(4-fluorophenyl)-5-(1-methyl-ethyl)-1H-pyrrol-1-yl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;
- trans-6-[2-[2-cyclopropyl-5-(4-fluorophenyl)-1H-pyrrol-1-yl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;
- trans-6-[2-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-pyrrol-1-yl]ethyl]tetrahydro-4hydroxy-2H-pyran-2-one;
- trans-tetrahydro-4-hydroxy-6-[2-[2-(2-methoxyphenyl)-5-methylethyl)-1H-pyrrol-1-yl]ethyl]-2H-pyran-2-one;
- trans-tetrahydro-4-hydroxy-6-[2-[2-(2-methyl-5-(1-naphthalenyl)-1H-pyrrol-1-yl]ethyl-9 -2H-pyran-2 -one;
- trans-6-[2-(2-bicyclo[2.2.1]hept-5-en-2-yl-5-methyl-1H-pyrrol-1yl)ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one;
- trans(.+-.)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4 -diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide;
- (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide;
- trans-2-(4-fluorophenyl)-N,4-diphenyl-1-[2(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-5-trifluoromethyl-1H-pyrrole-3-carboxamide; and
- trans-5-(4-fluorophenyl)-N,4-diphenyl-1-[2(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]2trifluoromethyl-1H-pyrrole-3-carboxamide.
- 12. A process for the preparation of the compound of Formula I.sub.a ##STR60## and the hydroxy acid and pharmaceutically acceptable salts thereof, corresponding to the opened lactone ring of the compound of Formula I.sub.a which comprises:
- (a) reacting the compound of Formula XVII ##STR61## with a compound of Formula ##STR62## wherein R.sub.7 and R.sub.8 are independently hydrogen alkyl of from one to three carbon atoms, phenyl or R.sub.7 and R.sub.8 are taken together as --(CH.sub.2).sub.n --wherein n is 4 or 5, and R.sub.13 is hydrogen or ##STR63## in an inert solvent and treating the resulting intermediate with a 10 % aqueous solution of hydrochloric acid to afford the compound of Formula I.sub.a ;
- (b) and if desired, converting the resulting compound of Formula I.sub.a to a hydroxy acid corresponding to the opened lactone ring of structural Formula I.sub.a by conventional hydrolysis and further, if desired, converting the hydroxy acid to a corresponding pharmaceutically acceptable salt by conventional means, and if so desired, converting the hydroxy acid to a compound of Formula I.sub.a by heating in an inert solvent.
- 13. A process according to claim 12 wherein the acid in Step (a) is hydrochloric acid.
- 14. A process according to claim 12 and for the preparation of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-]2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole3-carboxamide.
Parent Case Info
This is a continuation-in-part of U.S. application Ser. No. 158,439, filed Feb. 22, 1988.
US Referenced Citations (2)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0179559 |
Mar 1986 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Majewski et al., Tetrahedron Letters, 25, 1984, pp. 2101-2104. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
158439 |
Feb 1988 |
|